<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Imaging Biometrics Limited — News on 6ix</title>
<link>https://6ix.com/company/imaging-biometrics-limited</link>
<description>Latest news and press releases for Imaging Biometrics Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 13 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/imaging-biometrics-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d580e7beedb30cb6f8a552.webp</url>
<title>Imaging Biometrics Limited</title>
<link>https://6ix.com/company/imaging-biometrics-limited</link>
</image>
<item>
<title>AMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/amendement-to-notice-of-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/amendement-to-notice-of-annual-general-meeting</guid>
<pubDate>Wed, 13 May 2026 06:00:00 GMT</pubDate>
<description>Imaging Biometrics Limited has issued an amendment to its Notice of Annual General Meeting, correcting an error regarding a proposed share sub-division. The ordinary shares of £0.01 will be sub-divided into one ordinary share of £0.005, not £0.0005 as previously stated. The total number of ordinary shares in issue will remain 246,709,789, assuming the resolution passes at the AGM scheduled for June 3, 2026. All other resolutions remain unchanged.
Disclaimer*</description>
</item>
<item>
<title>NOTICE OF ANNUAL GENERAL MEETING</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/notice-of-annual-general-meeting-237</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/notice-of-annual-general-meeting-237</guid>
<pubDate>Tue, 12 May 2026 13:24:00 GMT</pubDate>
<description>Imaging Biometrics Limited will hold its Annual General Meeting on June 3, 2026, where a proposed share sub-division will be discussed, changing each £0.01 ordinary share into one £0.0005 ordinary share without altering the total of 246,709,789 shares outstanding.
Disclaimer*</description>
</item>
<item>
<title>KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/kirkstall-awarded-bbsrcnc3rs-grant-glioblastoma</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/kirkstall-awarded-bbsrcnc3rs-grant-glioblastoma</guid>
<pubDate>Fri, 08 May 2026 06:00:00 GMT</pubDate>
<description>Imaging Biometrics Limited announced that its subsidiary, Kirkstall Limited, has been awarded a BBSRC/NC3Rs grant to partner with Nottingham Trent University on developing a glioblastoma 'tumour on a chip' model. This research aims to create a more accurate, human-relevant platform for testing glioblastoma treatments, potentially improving drug development success rates and reducing animal testing. The company views this grant as validation of its acquisition strategy, integrating Kirkstall's or</description>
</item>
<item>
<title>Annual Report for the Year Ended 31 December 2025</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/annual-report-for-the-year-ended-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/annual-report-for-the-year-ended-31-december-2025</guid>
<pubDate>Thu, 30 Apr 2026 15:18:00 GMT</pubDate>
<description>Imaging Biometrics Limited has published its audited annual report for the year ended 31 December 2025, reporting revenue of £788,148, a 5% increase from £750,105 in 2024, with the majority generated by Imaging Biometrics, LLC. The company fully acquired Kirkstall Limited on 14 October 2025 and implemented cost reductions, including director fees, to lower cash burn. A Phase 1 clinical trial met its objectives and is complete, with resources now refocused on core operations, and next-generation </description>
</item>
<item>
<title>Board Appointment</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/board-appointment-164</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/board-appointment-164</guid>
<pubDate>Thu, 19 Feb 2026 10:48:00 GMT</pubDate>
<description>Imaging Biometrics Limited announced the appointment of John Charles Richardson as a Non-Executive Director, effective March 1, 2026, who will also join the remuneration and audit committees. Richardson brings over 40 years of experience in technology, operations, and strategic management, with a strong track record in engineering management and executive roles across technology companies. He currently holds directorships at ChampagneWebs Limited and Gyrometric Systems Limited and has previously</description>
</item>
<item>
<title>Update and IB Nimble Webinar – 27 February 2026</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/update-and-ib-nimble-webinar-27-february-2026</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/update-and-ib-nimble-webinar-27-february-2026</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Imaging Biometrics Limited (IBAI) provided a company update, acknowledging shareholder frustration and outlining a strategic shift to focus on core products. The company reported that Kirkstall Limited's sales increased by 84% to £123k in 2025 from £67k in 2024, driven by new distributor agreements in China, South Korea, and the United States. IBAI's core products, IB Clinic and IB Nimble, are seeing initial adoption and upcoming releases with new features, while QSMetric is being prepared for t</description>
</item>
<item>
<title>IBAI: Strategic Direction Fueling Organic Growth</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/ibai-strategic-direction-fueling-organic-growth</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/ibai-strategic-direction-fueling-organic-growth</guid>
<pubDate>Fri, 16 Jan 2026 07:00:00 GMT</pubDate>
<description>Imaging Biometrics Limited is shifting its strategic focus from a Phase 2 clinical trial for gallium maltolate to prioritize near-term commercial objectives for its imaging solutions, believing this will better serve shareholders. While the Phase 1 trial for oral gallium maltolate in recurrent glioblastoma is nearing completion with results being prepared for publication, the company has decided not to proceed with further clinical development of this therapeutic. Imaging Biometrics retains valu</description>
</item>
<item>
<title>Expansion Global Distribution Agreement with GE</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/expansion-global-distribution-agreement-with-ge</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/expansion-global-distribution-agreement-with-ge</guid>
<pubDate>Wed, 10 Dec 2025 09:43:00 GMT</pubDate>
<description>Imaging Biometrics Limited has expanded its global distribution agreement with GE HealthCare to include FTB Express maps and QSMetric, enhancing access to advanced neuroimaging solutions. This amendment builds upon the existing distribution of IB Neuro and Delta T1 maps, which are crucial for brain tumor diagnosis and treatment monitoring. FTB Express offers accelerated processing for Fractional Tumor Burden maps, providing rapid insights into tumor versus non-tumor tissue and treatment effects.</description>
</item>
<item>
<title>Release of Next-Generation IB Clinic</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/release-of-next-generation-ib-clinic</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/release-of-next-generation-ib-clinic</guid>
<pubDate>Wed, 26 Nov 2025 14:50:00 GMT</pubDate>
<description>Imaging Biometrics Limited has announced the release of its next-generation IB Clinic, a comprehensive image processing suite that significantly enhances automation, scalability, and workflow integration across its imaging technologies. This new version offers hands-free, platform-independent functionality, consolidating IB's plugin capabilities into a streamlined solution that reduces manual steps and ensures consistent, reproducible results. The release includes expanded imaging capabilities s</description>
</item>
<item>
<title>Board Changes</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/board-changes-450</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/board-changes-450</guid>
<pubDate>Mon, 24 Nov 2025 09:56:00 GMT</pubDate>
<description>Imaging Biometrics Limited announced that Dr. Al Musella will step down from the Board of Directors effective December 31, 2025, but will remain closely involved with the company's wholly owned subsidiary, Imaging Biometrics LLC, as a Medical Advisor. In this new capacity, Dr. Musella will provide clinical insight and strategic input to product development and marketing efforts, and the Board looks forward to continuing their collaboration.
Disclaimer*</description>
</item>
<item>
<title>Fractional Tumor Burden Mapping Enhances GBM Trial</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/fractional-tumor-burden-mapping-enhances-gbm-trial</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/fractional-tumor-burden-mapping-enhances-gbm-trial</guid>
<pubDate>Thu, 13 Nov 2025 11:24:00 GMT</pubDate>
<description>Imaging Biometrics Limited is enhancing a glioblastoma clinical trial by utilizing its Functional Tumor Burden (FTB) mapping technology to assess early treatment response, a development partly funded by the Musella Foundation for Brain Tumor Research & Information, Inc. This phase 2 feasibility study investigates administering temozolomide chemotherapy before radiation therapy, aiming to validate early objective response rates as reliable surrogates for drug activity, which could significantly s</description>
</item>
<item>
<title>IB Announces Completion of Phase 1 Trial of GaM</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/ib-announces-completion-of-phase-1-trial-of-gam</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/ib-announces-completion-of-phase-1-trial-of-gam</guid>
<pubDate>Mon, 10 Nov 2025 15:14:00 GMT</pubDate>
<description>Imaging Biometrics Limited has successfully completed its Phase 1 clinical trial for oral gallium maltolate (GaM) in recurrent glioblastoma, meeting all safety, tolerability, and pharmacokinetic objectives with no significant adverse events observed in the 26 enrolled patients, 22 of whom were included in a preliminary efficacy assessment. The trial demonstrated GaM's favorable safety profile and potential clinical benefit, encouraging the company to initiate a Phase 2 trial to further evaluate </description>
</item>
<item>
<title>Further Re: Purchase of interest in Kirkstall Ltd</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/further-re-purchase-of-interest-in-kirkstall-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/further-re-purchase-of-interest-in-kirkstall-ltd</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Imaging Biometrics Limited announced a variation to its sales and purchase agreement with Truetide PLC regarding the purchase of shares in Kirkstall Limited. Truetide has agreed to write off loan balances previously owed by Kirkstall, totaling £220,853.67, which includes £28,500 owed to The Ridings Early Growth Investment Company Limited. These loans had been written down to zero in Truetide's accounts for the year ended March 31, 2025. As a result of the write-offs, Kirkstall now has net assets</description>
</item>
<item>
<title>Purchase of Kirkstall and CLN - Correction</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/purchase-of-kirkstall-and-cln-correction</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/purchase-of-kirkstall-and-cln-correction</guid>
<pubDate>Tue, 14 Oct 2025 11:15:00 GMT</pubDate>
<description>Imaging Biometrics Limited (IBAI) has issued a correction to its previous announcement regarding the purchase of Kirkstall Limited and a convertible loan note (CLN) with Truetide plc. The correction pertains to the conversion price of the CLN, which is £0.0075 per Ordinary Share. The CLN bears interest at 6% per annum, accruing and adding to the loan balance. The loan is unsecured and subordinated and can be converted into IBAI Ordinary Shares at Truetide's discretion, either wholly or partially</description>
</item>
<item>
<title>Vivan Therapeutics and IB Announce Partnership</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/vivan-therapeutics-and-ib-announce-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/vivan-therapeutics-and-ib-announce-partnership</guid>
<pubDate>Fri, 03 Oct 2025 11:16:00 GMT</pubDate>
<description>Imaging Biometrics and Vivan Therapeutics have announced a strategic partnership to explore new anti-cancer uses for gallium maltolate. Imaging Biometrics will supply gallium maltolate for evaluation using Vivan's in vivo avatar cancer models. The initial focus will be on colorectal cancer, extending to pancreatic, lung, and other gastrointestinal cancers. Imaging Biometrics is evaluating next steps for clinical development after closing the Phase 1 trial in oral gallium maltolate for adult glio</description>
</item>
<item>
<title>IB Enters Agreement with MedImageMetric</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/ib-enters-agreement-with-medimagemetric</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/ib-enters-agreement-with-medimagemetric</guid>
<pubDate>Tue, 16 Sep 2025 14:49:00 GMT</pubDate>
<description>Imaging Biometrics has entered into an agreement with MedImageMetric to commercialize QSMetric, its patented quantitative susceptibility mapping (QSM) software, available immediately via annual license. QSMetric, an FDA-cleared MRI technique, quantifies changes in magnetic susceptibility, offering insights into various disease markers. A recent study demonstrated QSM's role in managing neurodegenerative diseases. QSMetric is well-placed to address a US diagnostics market worth over $3.5 billion,</description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/half-year-report-771</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/half-year-report-771</guid>
<pubDate>Wed, 13 Aug 2025 10:48:00 GMT</pubDate>
<description>Half-year Report.</description>
</item>
<item>
<title>Grant of Share Options</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/grant-of-share-options-88</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/grant-of-share-options-88</guid>
<pubDate>Thu, 07 Aug 2025 10:22:00 GMT</pubDate>
<description>Grant of Share Options.</description>
</item>
<item>
<title>IB Announces Soft Close to Phase 1 Trial</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/ib-announces-soft-close-to-phase-1-trial</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/ib-announces-soft-close-to-phase-1-trial</guid>
<pubDate>Mon, 21 Jul 2025 06:00:00 GMT</pubDate>
<description>IB Announces Soft Close to Phase 1 Trial.</description>
</item>
<item>
<title>Director/PDMR Dealing</title>
<link>https://6ix.com/company/imaging-biometrics-limited/news/directorpdmr-dealing-71</link>
<guid isPermaLink="true">https://6ix.com/company/imaging-biometrics-limited/news/directorpdmr-dealing-71</guid>
<pubDate>Wed, 09 Jul 2025 16:14:00 GMT</pubDate>
<description>Director/PDMR Dealing.</description>
</item>
</channel>
</rss>